Ocular Therapeutix (NSDQ:OCUL) has closed an underwritten public offering of 7,475,000 shares of its common stock at $5.00 apiece, reeling in $35.1 million to fund the planned resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year. The Bedford, Mass.-based company also plans to use its newly-acquired funds […]
Funding Roundup
Senseonics prices $50m notes offering, touts Q4 and full-year prelims
Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5 million in notes to cover over-allotments. The notes, which mature on Feb. 1, 2023, will be convertible into shares of Senseonics’ common stock at approximately $3.40 […]
Ocular Therapeutix plans $32.5m public offering to fund NDA resubmission for Dextenza
Updated to include the offering’s pricing information. Ocular Therapeutix (NSDQ:OCUL) said today that it plans to launch an underwritten public offering of 6.5 million shares of common stock at $5.00 apiece to help fund the resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year. The Bedford, Mass.-based […]
Philips joins $9m round for remote-care co LindaCare
Digital health company LindaCare has landed an $8.7 million Series B round, with investments made by Philips (NYSE:PHG), PMV, Capricorn ICT Arkiv, Connecticut Innovations and others. The Belgium-based company said it plans to use the newly-acquired funds to accelerate its U.S. market expansion and product commercialization, as well as build out its existing patient monitoring software platform […]
Neuspera Medical raises $26m Series B for injectable neuromod device
Neuspera Medical said today that it raised a $26 million Series B round for the injectable neuromodulation devices it’s developing. Formerly known as Vivonda Medical, San Jose, Calif.-based Neuspera said the round was led by 6 Dimensions Capital, joined by all of its Series A investors, including Action Potential Venture Capital and Windham Venture Partners, and new […]
Gecko Biomedical wins $7m French grant for tissue reconstruction tech
Gecko Biomedical said today that it won a French grant worth roughly $7 million has (€6 million) for the tissue reconstruction technology it’s developing. Paris-based Gecko said it plans to use the grant to commercialize its portfolio of synthetic light-activated polymers, which are designed to be biocompatible and bioresorbable and act as an adhesive, barrier or filler […]
Aerie Pharmaceuticals prices $75m public offering
Aerie Pharmaceuticals (NSDQ:AERI) has priced an underwritten public offering of $75 million in shares of its common stock. The Irvine, Calif.-based company also plans to grant underwriters a 30-day option to buy up to $11.3 million in shares of common stock. Get the full story at our sister site, Drug Delivery Business News.
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Centinel Spine reports $132m funding round
Fresh from its acquisition of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets, Centinel Spine last week reported raising more than $132 million. In the waning days of 2017, Centinel it closed its acquisition of DePuy’s Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems. Although the purchase price remained undisclosed, Centinel said at […]
Pavmed prices $4.3m offering
Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net […]
Obalon preps $35m offering
Obalon Therapeutics (NSDQ:OBLN) said this week that it’s planning a share flotation worth $35 million that could swell by another $5 million if an over-allotment option is fulfilled. The San Diego-based medical device company won pre-market approval from the FDA for its ingestible, gas-filled weight-loss balloon in September 2016. The Obalon device is indicated for weight loss in adults 30 to […]